1. SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023.
- Author
-
Carreño JM, Wagner AL, Monahan B, Singh G, Floda D, Gonzalez-Reiche AS, Tcheou J, Raskin A, Bielak D, Morris S, Fried M, Yellin T, Sullivan L, Sordillo EM, Gordon A, van Bakel H, Simon V, and Krammer F
- Subjects
- Humans, New York City epidemiology, Seroepidemiologic Studies, Male, Female, Adult, Middle Aged, Aged, Cross-Sectional Studies, Young Adult, Adolescent, Child, Pandemics, Child, Preschool, Infant, Aged, 80 and over, COVID-19 Vaccines immunology, COVID-19 epidemiology, COVID-19 immunology, Antibodies, Viral blood, Antibodies, Viral immunology, SARS-CoV-2 immunology, SARS-CoV-2 isolation & purification, Spike Glycoprotein, Coronavirus immunology
- Abstract
Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF